Biosimilars Market Expansion Projected to Drive $100 Billion in Healthcare Savings

NeoGraph Analytics today announced the publication of its Global Biosimilars Market Report, projecting that biosimilar adoption will generate over $100 billion in cumulative healthcare system savings through 2030 as patent expirations accelerate for high-cost biologic therapies. The research analyzes market dynamics across therapeutic areas including oncology, immunology, diabetes, and ophthalmology, where biosimilars are poised to offer cost-effective alternatives to reference biologics. The report documents 45 biosimilar approvals in major markets during 2025, with robust pipelines targeting blockbuster drugs facing patent expiration. Dr. Lisa Anderson, Biopharma Market Intelligence Director at NeoGraph Analytics, commented: "We're reaching an inflection point in biosimilar market development. Regulatory pathways are well-established, manufacturing capabilities have matured, and payer incentives increasingly favor biosimilar utilization. The next wave of biosimilar competition will target some of the world's highest-revenue biologics, creating unprecedented pricing pressure." Market adoption varies significantly across regions, with European markets achieving 60-80% biosimilar penetration for established products, while U.S. adoption remains lower but accelerating due to policy reforms and pharmacy benefit management strategies. Interchangeability designations from the FDA are removing key prescriber concerns about switching patients from reference products. The report examines competitive strategies employed by both biosimilar manufacturers and originator companies, including authorized biosimilars, value-based contracting, and patient support programs. NeoGraph Analytics' analysis provides detailed market forecasts, competitive intelligence, and strategic insights for pharmaceutical companies, healthcare providers, and payers navigating the evolving biologics landscape.